Objective
Colistimethate Sodium (CMS hereinafter) is a rapidly bactericidal antimicrobial agent with a significant post-antibiotic effect against multidrug resistant Gram-negative pathogens. CMS represents a reliable alternative for the treatment of life-threatening nosocomial infections but today the market supply of CMS relies on industrial processes based on freeze drying of CMS aqueous solutions. This represents outstanding energetic costs that directly affect the final price of CMS.
CIDQO is an SME founded in 2012 and its PhD staff has a wide expertise and know-how on the development and scaling-up of chemical processes, as well as on custom manufacturing of active pharmaceutical ingredients. CIDQO aims to undertake an innovation project to solve the current limitations of CMS supply, through the industrial validation of a new processing technology based on the combination of ultrafiltration and evaporation coupled to HPLC/LC-MS. The key market opportunity of the new processing technology relies on its ability to deliver a non-pyrogenic and sterile CMS formulation to be commercialized on the Pharmaceutical and Veterinary medicine markets, which will represent several advantages in terms of price and quality compared with the current commercial form.
The overall plan to reach the market needs to be defined in the short term since the innovation process is next to finish. Phase 1 of SME Instrument represents a good opportunity to get the financial support required to perform a thorough market study not only to minimize risks but also to set up a business plan for commercialization. The main objective is to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form to be delivered by the new processing technology. The actual market chances that can be exploited to maximize the economic returns will be analyzed and a detailed business plan will be developed.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- agricultural sciences veterinary sciences
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- natural sciences chemical sciences inorganic chemistry alkali metals
- social sciences economics and business business and management business models
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08490 TORDERA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.